From the Journals

New PsA questionnaire fails to beat existing early screening methods

Publish date: April 12, 2018

 

FROM JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY


AbbVie supported this study with an educational grant. The study was supported by the National Institute for Health Research Leeds Biomedical Research Centre. Some of the authors reported potential conflicts of interest.

SOURCE: Coates L et al. J Eur Acad Dermatol Venereol. 2018 Mar 26. doi: 10.1111/jdv.14971.

Pages

Recommended Reading

Ultrasound study supports deep Koebner mechanism in PsA pathology
Psoriatic Arthritis Resource Center
Arthritis limits physical activity the most in the South
Psoriatic Arthritis Resource Center
FDA approves IL-23 antagonist for plaque psoriasis
Psoriatic Arthritis Resource Center
FDA approves certolizumab label update for pregnancy, breastfeeding
Psoriatic Arthritis Resource Center
Study using U.K. data quantifies infection risk associated with psoriasis
Psoriatic Arthritis Resource Center
TB in 2017: Good news and bad news
Psoriatic Arthritis Resource Center
Most PsA patients discontinue initial biologic within 12 months
Psoriatic Arthritis Resource Center
MDedge Daily News: Does more marijuana mean fewer opioids?
Psoriatic Arthritis Resource Center
Reassurance for women taking certolizumab during pregnancy
Psoriatic Arthritis Resource Center
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
Psoriatic Arthritis Resource Center

Related Articles

  • Latest News

    Dr. Jashin J. Wu

    Make a PEST of your psoriasis patients

    Author:
    Bruce Jancin
    Publish date: February 6, 2018

    KAUAI, HAWAII – Every psoriasis patient should complete the Psoriasis Epidemiology Screening Tool (PEST) for psoriatic arthritis annually.